BLTE IPOs 6.90M* ADSs @$6.00: https://finance.yahoo.com/news/belite-bio-announces-pricing-36-225900534.html?.tsrc=fin-srch Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, and metabolic diseases. *Assuming exercise of underwriter’s option.